Proceedings of the Ninth International Conference of Drug Regulatory Authorities (ICDRA) - Berlin, Germany 25-29 April 1999
(1999; 102 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuOpening Ceremony
Fermer ce répertoireGood regulatory practice
Afficher le documentNational challenges: pharmaceutical sector reform
Afficher le documentRegional approaches to regulation in Europe
Afficher le documentRecommendations
Ouvrir ce répertoire et afficher son contenuGood certification practice
Ouvrir ce répertoire et afficher son contenuCounterfeit drugs: challenges and solutions
Ouvrir ce répertoire et afficher son contenuCurrent issues in regulation and quality
Ouvrir ce répertoire et afficher son contenuInternational Conference on Harmonization: implementation and implications
Ouvrir ce répertoire et afficher son contenuDrug utilization studies
Ouvrir ce répertoire et afficher son contenuInternational Conference on Harmonization and the common technical document
Ouvrir ce répertoire et afficher son contenuKeynote address
Ouvrir ce répertoire et afficher son contenuGlobal and national efforts to reduce tobacco use
Ouvrir ce répertoire et afficher son contenuElectronic communication in the regulatory process
Ouvrir ce répertoire et afficher son contenuTransparency in monitoring the safety of medicines
Ouvrir ce répertoire et afficher son contenuPharmaceutical products for use in special groups
Ouvrir ce répertoire et afficher son contenuNeed for Bioequivalence
Ouvrir ce répertoire et afficher son contenuAntimicrobial resistance: battling the bugs
Ouvrir ce répertoire et afficher son contenuSafety issues of plasma-derived medicinal products
Ouvrir ce répertoire et afficher son contenuHerbal medicines
Ouvrir ce répertoire et afficher son contenuRegulation and access to essential drugs
Afficher le documentParticipants
Afficher le documentBack cover
 

Recommendations

1. WHO should develop guidelines to define good regulatory practice and develop appropriate indicators to measure performance. These guidelines should be made available over the WHO website to enable countries to formulate their own standard operating procedures (SOPS).

2. In order to implement good regulatory practice:


• The mission and objectives of drug regulation should be stated clearly so that the attainment of perceived objectives can be assessed adequately.

• Regulatory procedures and outcomes should be transparent to all the stakeholders, including those affected by such regulation, professional bodies, and the public.

• Drug evaluation reports including the rationale used to reach decisions concerning regulatory action should be accessible to the public, as applicable within national legislation.

• The deadline required for the assessment of drug applications should be reasonable, without compromising the safety, efficacy and quality of the product.

• Special considerations should be made to expedite the review of orphan drugs and drugs of special medical or public health value.

• Regulatory authorities should be accountable to the government, those regulated and the public.

• Personnel engaged in drug regulation should be appropriately trained, qualified, competent and of high integrity. Merit-based selection criteria of a high standard should be implemented. Human resource development programmes should be in place to improve the knowledge and skills of staff.

• In the event of dissatisfaction with regulatory decisions, legislative procedures and mechanisms should be in place to allow pharmaceutical companies, consumer groups and the public to lodge official complaints and appeals.

• Access to the latest scientific and technological information should be provided to drug regulatory authorities in order to facilitate their work.

• Regulatory authorities should acknowledge the rights of citizens to receive accurate and relevant information on drugs that are marketed in the country.

• Regulatory authorities should establish mechanisms to ensure the quality of the procedures they operate to.

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013